Can-Fite BioPharma (CANF) announced the completion of a comprehensive analysis of its current partnerships and the market potential for its lead drug candidates, Piclidenoson and Namodenoson upon regulatory approvals. “While we emphasize these figures are derived from our forecasts and subject to inherent uncertainties of drug development and commercialization, we remain highly encouraged by these projections. They underscore the robust strategic foundation that we have built through our diverse collaborations, reflecting both the significant commercial opportunities and potential long-term value we aim to deliver to our shareholders”, stated Can-Fite VP Business Development Dr. Sari Fishman.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CANF:
- Can-Fite BioPharma Reports 2024 Financial Results and Clinical Advances
- Can-Fite BioPharma reports FY24 EPS 0c vs 1c last year
- Can-Fite BioPharma initiates Phase 3 psoriasis study of piclidenoson
- CANF Earnings this Week: How Will it Perform?
- Can-Fite BioPharma Advances Canine Osteoarthritis Treatment with Vetbiolix Partnership